Cargando…

Metabolomics Profiles Reveal the Efficacy of Wuzhuyu Decoction on Patients with Chronic Non-Atrophic Gastritis

OBJECTIVE: Chronic non-atrophic gastritis (CNAG) is a common clinical gastrointestinal disease with a long and recurrent course. In China, Wuzhuyu decoction (WZYD) has been used for centuries to treat gastrointestinal disorders. To unravel the efficacy and mechanism of WZYD for CNAG, a clinical stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Qichao, Zeng, Jinhao, Zhang, Xiaomei, He, Tingting, Zhang, Aozhe, Li, Jianyu, Wei, Shizhang, Jing, Manyi, Li, Haotian, Wang, Xin, Chang, Lei, Ma, Xiao, Zhao, Yanling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638898/
https://www.ncbi.nlm.nih.gov/pubmed/37954485
http://dx.doi.org/10.2147/DDDT.S428783
_version_ 1785133695922864128
author Hu, Qichao
Zeng, Jinhao
Zhang, Xiaomei
He, Tingting
Zhang, Aozhe
Li, Jianyu
Wei, Shizhang
Jing, Manyi
Li, Haotian
Wang, Xin
Chang, Lei
Ma, Xiao
Zhao, Yanling
author_facet Hu, Qichao
Zeng, Jinhao
Zhang, Xiaomei
He, Tingting
Zhang, Aozhe
Li, Jianyu
Wei, Shizhang
Jing, Manyi
Li, Haotian
Wang, Xin
Chang, Lei
Ma, Xiao
Zhao, Yanling
author_sort Hu, Qichao
collection PubMed
description OBJECTIVE: Chronic non-atrophic gastritis (CNAG) is a common clinical gastrointestinal disease with a long and recurrent course. In China, Wuzhuyu decoction (WZYD) has been used for centuries to treat gastrointestinal disorders. To unravel the efficacy and mechanism of WZYD for CNAG, a clinical study was conducted. And metabolomics was used to explore the mechanism of WZYD for CNAG patients. METHODS: Twenty patients in total were recruited in this study (Nos. ChiCTR2200062296) and the protocol was approved by the Ethics Committee (Approval number: KY-2022-2-6-1) and complied with the Declaration of Helsinki. The formula granule of WZYD were assessed by UHPLC-QQQ-TOF to discern the main potential active compounds. The endoscopy evaluation and histopathological changes were detected as effective indicators. Serum samples from patients were used for metabolomics. Inflammatory factors in patients’ serum were determined by ELISA. Metabolomics revealed a series of differential metabolites and signaling pathways. RESULTS: WZYD was capable to prevent CNAG by ameliorating score of endoscopy evaluation including erosion, hemorrhage, as well as chronic inflammation and active chronic inflammation score after treatment were decreased. The results indicated that 10 core metabolic components were associated with the treatment of WZYD. Moreover, these metabolic components proved that pyrimidine metabolism and thiamine metabolism were critically responsible for CNAG. In addition, WZYD treatment effectively reduced serum levels of TNF-α, IL-10, and COX-2. CONCLUSION: Altogether, WZYD can effectively alleviate CNAG by inhibiting inflammation and regulating related metabolic processes, which might be the molecular mechanism of WZYD treatment of CNAG. More studies are warranted to be conducted in this area. TRIAL REGISTRATION: ChiCTR, ChiCTR2200062296. Registered 1 August 2022, https://www.chictr.org.cn/com/25/showprojen.aspx?proj=174027.
format Online
Article
Text
id pubmed-10638898
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-106388982023-11-11 Metabolomics Profiles Reveal the Efficacy of Wuzhuyu Decoction on Patients with Chronic Non-Atrophic Gastritis Hu, Qichao Zeng, Jinhao Zhang, Xiaomei He, Tingting Zhang, Aozhe Li, Jianyu Wei, Shizhang Jing, Manyi Li, Haotian Wang, Xin Chang, Lei Ma, Xiao Zhao, Yanling Drug Des Devel Ther Original Research OBJECTIVE: Chronic non-atrophic gastritis (CNAG) is a common clinical gastrointestinal disease with a long and recurrent course. In China, Wuzhuyu decoction (WZYD) has been used for centuries to treat gastrointestinal disorders. To unravel the efficacy and mechanism of WZYD for CNAG, a clinical study was conducted. And metabolomics was used to explore the mechanism of WZYD for CNAG patients. METHODS: Twenty patients in total were recruited in this study (Nos. ChiCTR2200062296) and the protocol was approved by the Ethics Committee (Approval number: KY-2022-2-6-1) and complied with the Declaration of Helsinki. The formula granule of WZYD were assessed by UHPLC-QQQ-TOF to discern the main potential active compounds. The endoscopy evaluation and histopathological changes were detected as effective indicators. Serum samples from patients were used for metabolomics. Inflammatory factors in patients’ serum were determined by ELISA. Metabolomics revealed a series of differential metabolites and signaling pathways. RESULTS: WZYD was capable to prevent CNAG by ameliorating score of endoscopy evaluation including erosion, hemorrhage, as well as chronic inflammation and active chronic inflammation score after treatment were decreased. The results indicated that 10 core metabolic components were associated with the treatment of WZYD. Moreover, these metabolic components proved that pyrimidine metabolism and thiamine metabolism were critically responsible for CNAG. In addition, WZYD treatment effectively reduced serum levels of TNF-α, IL-10, and COX-2. CONCLUSION: Altogether, WZYD can effectively alleviate CNAG by inhibiting inflammation and regulating related metabolic processes, which might be the molecular mechanism of WZYD treatment of CNAG. More studies are warranted to be conducted in this area. TRIAL REGISTRATION: ChiCTR, ChiCTR2200062296. Registered 1 August 2022, https://www.chictr.org.cn/com/25/showprojen.aspx?proj=174027. Dove 2023-11-07 /pmc/articles/PMC10638898/ /pubmed/37954485 http://dx.doi.org/10.2147/DDDT.S428783 Text en © 2023 Hu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Hu, Qichao
Zeng, Jinhao
Zhang, Xiaomei
He, Tingting
Zhang, Aozhe
Li, Jianyu
Wei, Shizhang
Jing, Manyi
Li, Haotian
Wang, Xin
Chang, Lei
Ma, Xiao
Zhao, Yanling
Metabolomics Profiles Reveal the Efficacy of Wuzhuyu Decoction on Patients with Chronic Non-Atrophic Gastritis
title Metabolomics Profiles Reveal the Efficacy of Wuzhuyu Decoction on Patients with Chronic Non-Atrophic Gastritis
title_full Metabolomics Profiles Reveal the Efficacy of Wuzhuyu Decoction on Patients with Chronic Non-Atrophic Gastritis
title_fullStr Metabolomics Profiles Reveal the Efficacy of Wuzhuyu Decoction on Patients with Chronic Non-Atrophic Gastritis
title_full_unstemmed Metabolomics Profiles Reveal the Efficacy of Wuzhuyu Decoction on Patients with Chronic Non-Atrophic Gastritis
title_short Metabolomics Profiles Reveal the Efficacy of Wuzhuyu Decoction on Patients with Chronic Non-Atrophic Gastritis
title_sort metabolomics profiles reveal the efficacy of wuzhuyu decoction on patients with chronic non-atrophic gastritis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638898/
https://www.ncbi.nlm.nih.gov/pubmed/37954485
http://dx.doi.org/10.2147/DDDT.S428783
work_keys_str_mv AT huqichao metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis
AT zengjinhao metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis
AT zhangxiaomei metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis
AT hetingting metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis
AT zhangaozhe metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis
AT lijianyu metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis
AT weishizhang metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis
AT jingmanyi metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis
AT lihaotian metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis
AT wangxin metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis
AT changlei metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis
AT maxiao metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis
AT zhaoyanling metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis